Back

Featured Topics

Behind The Science
Breast Cancer
Cancer Immunotherapy
Hematology
Lung Cancer
Manufacturing
Multiple Sclerosis
Oncology
Ophthalmology
Partnering
Respiratory Health
Rheumatology
About Us Contact Us Leadership Awards & Recognition Investors Suppliers Compliance
  • Twitter
  • Facebook
  • LinkedIn

Shutting Down Pain


Read More Stories
Mar 23, 2015

Genentech


What if you never felt pain? Sounds great, right? "We need pain," says David Hackos, neuroscientist at Genentech, "in order to protect ourselves from injury." There are actually people in the world that can't feel pain. They’re not superheroes; in fact, their condition can make it difficult for them to avoid injuries. These unique people may offer a clue to understanding the biology of pain, as well as a new way to manage it.

In 2001, a company called Xenon began to analyze data from people who lacked sensitivity to pain; they discovered a genetic mutation that disabled a specific sodium channel called NaV 1.7. There are nine sodium channels in the body, but the surprising thing they learned from the genetics was that only NaV 1.7 was required to transmit pain signals to the brain.

We partnered with Xenon in 2012 to develop a novel sodium channel inhibitor that mimics this genetic mutation. The molecule targets NaV 1.7 by exploiting a mechanism in the voltage sensors that open and close the channel. This collaboration marks our first efforts towards a potential medicine to treat chronic pain. For more—including robots, gladiators, helicopters, and some rockstar scientists—watch the video below.

 


Tags:

  • Big Ideas,
  • Behind The Science

Read More Stories

Read about breakthrough science, the everyday people who make it happen, and the patients we serve.

?? of 40 moments published

  • Now Hiring
  • Find A Job
  • Professional Areas
  • Diversity & Inclusion
  • Chief Diversity Officer
  • Fostering Belonging
  • Advancing Inclusive Research & Health Equity
  • Transforming Society
  • Our 2021 Diversity & Inclusion Report
  • Our Work in Action
  • Kindergarten to Careers
  • For Scientists
  • Our Scientists
  • Publications
  • Oncology
  • Immunology
  • Neuroscience
  • Metabolism
  • Infectious Disease
  • Ophthalmology
  • For Patients
  • Our Medicines
  • Our Approach to Pricing
  • Patient Advocacy
  • Financial Support
  • Medicine Information Support
  • Create With Us
  • Clinical Trial Information
  • Genentech Patient Foundation
  • Disease Education
  • Advancing Inclusive Research
  • For Medical Professionals
  • Our Medicines & Products
  • Our Pipeline
  • Medical Resources
  • Clinical Trial Information
  • Sunshine Act Compliance
  • Product Security
  • For Partners
  • Our Approach
  • What We Are Looking For
  • Partner With Us
  • BIO 2022
  • Our Stories
  • For Media
  • News Features
  • Press Releases
  • Statements
  • Company Information
  • Sign Up For News Alerts
  • For Good
  • Giving
  • Diversity & Inclusion
  • Sustainability
  • About Us
  • Leadership
  • Policy & Advocacy
  • Our Focus on Oncology
  • Awards & Recognition
  • Investors
  • Suppliers
  • Our Approach to Pricing
  • CA Transparency in Supply
  • Compliance Overview
  • Contact Us
  • Call Us
  • Email Us
  • Visit us
  • Submit a Medical Inquiry
  • Submit a Media Inquiry
  • Privacy
  • Privacy Policy
  • Terms & Conditions
© 2022 Genentech, Inc. All rights reserved. This site is intended for US residents only.